Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial
Authors:
- Keith M. GodfreyKGKeith M. Godfrey
- NiPPeR Study GroupNGNiPPeR Study Group
Open Access
- 29 March 2021
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (5) , 1091-1099
Abstract
OBJECTIVE: Better preconception metabolic and nutritional health are hypothesized to promote gestational normoglycemia and reduce preterm birth, but evidence supporting improved outcomes with nutritional supplementation starting preconception is limited. RESEARCH DESIGN AND METHODS: This double-blind randomized controlled trial recruited from the community 1,729 U.K., Singapore, and New Zealand women aged 18–38 years planning conception. We investigated whether a nutritional formulation containing myo-inositol, probiotics, and multiple micronutrients (intervention), compared with a standard micronutrient supplement (control), taken preconception and throughout pregnancy could improve pregnancy outcomes. The primary outcome was combined fasting, 1-h, and 2-h postload glycemia (28 weeks gestation oral glucose tolerance test). RESULTS: Between 2015 and 2017, participants were randomized to control (n = 859) or intervention (n = 870); 585 conceived within 1 year and completed the primary outcome (295 intervention, 290 control). In an intention-to-treat analysis adjusting for site, ethnicity, and preconception glycemia with prespecified P < 0.017 for multiplicity, there were no differences in gestational fasting, 1-h, and 2-h glycemia between groups (β [95% CI] loge mmol/L intervention vs. control −0.004 [−0.018 to 0.011], 0.025 [−0.014 to 0.064], 0.040 [0.004–0.077], respectively). Between the intervention and control groups there were no significant differences in gestational diabetes mellitus (24.8% vs. 22.6%, adjusted risk ratio [aRR] 1.22 [0.92–1.62]), birth weight (adjusted β = 0.05 kg [−0.03 to 0.13]), or gestational age at birth (mean 39.3 vs. 39.2 weeks, adjusted β = 0.20 [−0.06 to 0.46]), but there were fewer preterm births (5.8% vs. 9.2%, aRR 0.43 [0.22–0.82]), adjusting for prespecified covariates. CONCLUSIONS: Supplementation with myo-inositol, probiotics, and micronutrients preconception and in pregnancy did not lower gestational glycemia but did reduce preterm birth.Keywords
Funding Information
- Medical Research Council
- National Medical Research Council
- Agency of Science, Technology and Research
- Gravida, a New Zealand Government Centre of Research Excellence
- Société des Produits Nestlé S.A.
This publication has 40 references indexed in Scilit:
- Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trialThe Journal of Maternal-Fetal & Neonatal Medicine, 2013
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) StudyDiabetes Care, 2012
- Frequency of Gestational Diabetes Mellitus at Collaborating Centers Based on IADPSG Consensus Panel–Recommended CriteriaDiabetes Care, 2012
- Patterns of fetal and infant growth are related to atopy and wheezing disorders at age 3 yearsThorax, 2010
- Reduced Time Points to Calculate the Composite IndexDiabetes Care, 2010
- International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in PregnancyDiabetes Care, 2010
- Revised birth centiles for weight, length and head circumference in the UK-WHO growth chartsAnnals of Human Biology, 2010
- International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in PregnancyDiabetes Care, 2010
- Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trialBritish Journal of Nutrition, 2008
- Epidemiology and causes of preterm birthThe Lancet, 2008